New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
04:55 EDTBMRN, BMRN, BMRN, BMRN, BMY, BMY, BMY, BMY, DNA, DNA, DNA, DNA, SNY, SNY, SNY, SNY, OVAS, OVAS, OVAS, OVAS, RHHBY, RHHBY, RHHBY, RHHBY, ADXS, ADXS, ADXS, ADXS, CPXX, CPXX, CPXX, CPXX, RARE, RARE, RARE, RARE, SGMO, SGMO, SGMO, SGMO, BLUE, BLUE, BLUE, BLUE, MRK, MRK, MRK, MRKBIO to hold a convention
BIO International Convention to be held in San Diego on June 23-26.
News For BMRN;BLUE;SGMO;RARE;CPXX;ADXS;RHHBY;OVAS;SNY;DNA;BMY;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 8, 2014
08:11 EDTMRKCubist volatility elevated into Merck acquiring for $8.4B in cash
Subscribe for More Information
08:08 EDTMRKMerck says about $9.5B of debt to be issued related to Cubist deal
Subscribe for More Information
07:35 EDTADXS, MRKAdvaxis reports FDA acceptance of IND application for ADXS-PSA combination trial
Subscribe for More Information
07:13 EDTMRKMerck to host conference call
Subscribe for More Information
07:11 EDTSGMOSangamo presents new data for Vivo Protein Replacement Platform
Sangamo announced the presentation of new preclinical data from its proprietary programs for the treatment of lysosomal storage disorders and Shire-partnered hemophilia program. These studies demonstrate the broad applicability of Sangamo's In Vivo Protein Replacement Platform for the potentially curative treatment of such diseases. The data presented at ASH from Sangamo's proprietary IVPRP applications demonstrated the efficient production, secretion and tissue uptake of functional iduronate-2-sulfatase and alpha-L-iduronidase, enzymes that are deficient in the LSDs, Hunter and Hurler's disease, respectively. Data were also presented from Sangamo's partnered program with Shire that demonstrated that therapeutic levels of Factor IX, the human clotting factor that is deficient in hemophilia B, could be generated in a dose-dependent manner in non-human primates. There were no significant alterations in circulating albumin levels. Studies in mice also demonstrated stable Factor IX production from Sangamo's IVPRP for over 1 year.
07:01 EDTMRKMerck to acquire Cubist for $102 per share in cash, or $9.5B
Subscribe for More Information
07:00 EDTMRKMerck to acquire Cubist for $102 per share in cash
Subscribe for More Information
05:53 EDTBMYStocks with implied volatility movement; BSX BMY
Subscribe for More Information
December 7, 2014
16:29 EDTMRKMerck in discussions to buy Cubist for $7B, Bloomberg reports
Subscribe for More Information
14:10 EDTBMYAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:06 EDTBMYBMY announces positive results in Phase 1b trial evaluating Opdivo
Subscribe for More Information
12:58 EDTMRKMerck presents KEYTRUDA data at ASH
Subscribe for More Information
December 6, 2014
09:19 EDTCPXXCelator Pharmaceuticals to hold a reception
Subscribe for More Information
December 5, 2014
12:33 EDTBLUEbluebird bio to host conference call
Subscribe for More Information
11:33 EDTRHHBYGenentech to present clinical data at ASH
Subscribe for More Information
10:22 EDTBMYBristol-Myers call activity attributed to takeover speculation
Subscribe for More Information
10:05 EDTBMYBristol-Myers jumps 2% amid talk of potential Pfizer bid
Shares of Bristol-Myers (BMY) are up in early trading amid chatter of a potential takeover bid from Pfizer (PFE). The stock is up $1.26 to $60.15. Bristol's market capitalization stands around $99B, less than twice that of Pfizer's $200B. A Jefferies analyst last week called Mylan (MYL) the most likely takeover target for Pfizer. Pfizer is "highly motivated" to buy a foreign company using its overseas cash and Mylan looks like the most likely target, Jefferies analyst Jeffrey Holford wrote.
09:56 EDTBMYRumor: Bristol-Myers strength attributed to takeover speculation
Subscribe for More Information
December 4, 2014
11:12 EDTSNYSanofi diabetes sales head left company, Bloomberg says
Subscribe for More Information
09:22 EDTBMRNBioMarin participates in a conference call with SunTrust
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use